Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.

Afolabi, Muhammed O; Ishola, David; Manno, Daniela; Keshinro, Babajide; Bockstal, Viki; Rogers, Baimba; Owusu-Kyei, Kwabena; Serry-Bangura, Alimamy; Swaray, Ibrahim; Lowe, Brett; +25 more... Kowuor, Dickens; Baiden, Frank; Mooney, Thomas; Smout, Elizabeth; Köhn, Brian; Otieno, Godfrey T; Jusu, Morrison; Foster, Julie; Samai, Mohamed; Deen, Gibrilla Fadlu; Larson, Heidi; Lees, Shelley; Goldstein, Neil; Gallagher, Katherine E; Gaddah, Auguste; Heerwegh, Dirk; Callendret, Benoit; Luhn, Kerstin; Robinson, Cynthia; Greenwood, Brian; Leyssen, Maarten; Douoguih, Macaya; Leigh, Bailah; Watson-Jones, Deborah; EBL3001 study group; (2021) Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infectious Diseases, 22 (1). pp. 110-122. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(21)00128-6

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(21)00128-6

Abstract

Share

Download

Filename: Afolabi_etal_2021_Safety-and-immunogenicity-of-the.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar